Evidence map›Paper›PMID 35055022›Full record

ReviewInternational journal of molecular sciences2022

Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions.

Melissa Jones, Corina Mihaela Ionescu, Daniel Walker, Susbin Raj Wagle, Bozica Kovacevic, Jacqueline Chester, Thomas Foster, Edan Johnston, Jafri Kuthubutheen, Daniel Brown and 4 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Type 2 diabetes mellitus, antidiabetics, and the risk of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Melissa JonesBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0002-2771-1158
Corina Mihaela IonescuBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0002-8966-0448
Daniel WalkerBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.
Susbin Raj WagleBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0001-9867-8896
Bozica KovacevicBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0002-9359-7840
Jacqueline ChesterBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0002-5528-2370
Thomas FosterBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.
Edan JohnstonBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.
Jafri KuthubutheenFiona Stanley Hospital, Murdoch, WA 6150, Australia.
Daniel BrownCurtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0001-6097-637X
Marcus D AtlasHearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Perth, WA 6009, Australia.
Momir MikovDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, 21101 Novi Sad, Serbia.
Armin MooranianBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.
Hani Al-SalamiBiotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0003-0049-6969
Curtin University · AUFiona Stanley Hospital · AUThe University of Western Australia · AUUniversity of Novi Sad · RS

Funding

Australian National Health and Medical Research APP9000597Beijing Nat-Med Biotechnology Co. Ltd n/aCurtin Faculty ORS-WAHAI Consortium n/aEuropean Union Horizon 2020 872370
6 · The paper itself

Abstract

Biguanides, particularly the widely prescribed drug metformin, have been marketed for many decades and have well-established absorption profiles. They are commonly administered via the oral route and, despite variation in oral uptake, remain commonly prescribed for diabetes mellitus, typically type 2. Studies over the last decade have focused on the design and development of advanced oral delivery dosage forms using bio nano technologies and novel drug carrier systems. Such studies have demonstrated significantly enhanced delivery and safety of biguanides using nanocapsules. Enhanced delivery and safety have widened the potential applications of biguanides not only in diabetes but also in other disorders. Hence, this review aimed to explore biguanides' pharmacokinetics, pharmacodynamics, and pharmaceutical applications in diabetes, as well as in other disorders.

Indexed as

Drug CarriersDrug CompoundingDrug Delivery SystemsTheranostic NanomedicineBiguanidesBile Acids and SaltsChronic DiseaseDrug DevelopmentHumansHypoglycemic AgentsMetforminBiguanidesBile Acids and SaltsDrug CarriersHypoglycemic AgentsMetforminbile acidsdiabetes mellitusencapsulationformulationmetforminpharmacodynamicspharmacokinetics

Identifiers

PMID35055022
PMCPMC8775521
OpenAlexW4205645168

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.